FINWIRES · TerminalLIVE
FINWIRES

$QGEN

15 stories mentioning QGENUpdated 15d ago

Every FINWIRES story that references QGEN, newest first.

What are analysts saying about QGEN?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on QGEN?

Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.4%.The iShares Biotechnology ETF (IBB) fell 2.7%.In corporate news, BioNTech (BNTX) said it terminated its phase 2 trial evaluating autogene cevumeran as an adjuvant monotherapy in people with colorectal cancer. The trial's independent safety board recommended discontinuing treatment and ending the trial, as further continuation was unlikely to change the efficacy outcome, the company said. Shares fell 8%.Eli Lilly (LLY) said the US Food and Drug Administration approved Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. Lilly shares were down 0.9%.10x Genomics (TXG) said a Delaware federal jury awarded the company more than $4.8 million after finding that three patents held through its Scale Biosciences unit were infringed by Parse Biosciences, a subsidiary of Qiagen (QGEN). 10x Genomics shares were down 5.2%, and Qiagen was shedding 1.3%.Quoin Pharmaceuticals (QNRX) reported "positive" interim data from its ongoing phase 2/3 study of QRX003 in patients with netherton syndrome, and also a private placement financing of up to $50.0 million. Shares surged 18%.

$BNTX$LLY$QGEN$QNRX$TXG
Sectors

Sector Update: Healthcare

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.4%.The iShares Biotechnology ETF (IBB) dropped 2.7%.In corporate news, 10x Genomics (TXG) said a Delaware federal jury awarded the company more than $4.8 million after finding that three patents held through its Scale Biosciences unit were infringed by Parse Biosciences, a subsidiary of Qiagen (QGEN). 10x Genomics shares were down 5.2%, and Qiagen was shedding 1.3%.

$QGEN$TXG
Wire

10x Genomics Announces $4.8 Million Award in Patent Case Against Qiagen Unit

10x Genomics (TXG) said a Delaware federal jury awarded the company more than $4.8 million after finding that three patents held through its Scale Biosciences unit were infringed by Parse Biosciences, a subsidiary of Qiagen (QGEN).The jury also rejected Parse's challenges to the patents' validity, confirming all three as valid and enforceable, 10x said Friday in a statement.The damages reflect a 14% royalty on sales of Parse's Evercode Whole Transcriptome products from 2021 through mid-2026, 10x said.10x plans to pursue additional remedies in post-trial proceedings, including enhanced damages, attorneys' fees and a permanent injunction against further infringement by Parse in the US.Qiagen didn't immediately reply to a request for comment from.10x shares fell 5.4% in Friday trading, and Qiagen dropped 1.3%.Price: $61.33, Change: $-3.52, Percent Change: -5.43%

$QGEN$TXG
Wire

Qiagen Names Jonathan Pratt as Chief Executive

Qiagen (QGEN) named Jonathan Pratt as chief executive officer, effective Sept. 1, to succeed Thierry Bernard, the company said Monday.Pratt most recently served as president and CEO of Filtration Group. His appointment as Qiagen CEO followed a comprehensive search process, the company said.Bernard agreed to support the transition through year-end.Qiagen reiterated its outlook for Q3 and 2026, and continues to review strategic opportunities, according to the statement.Price: $44.06, Change: $-0.02, Percent Change: -0.03%

$QGEN
Wire

Qiagen Q2 Adjusted Earnings, Revenue Rise

Qiagen (QGEN) reported Q2 adjusted earnings late Wednesday of $0.62 per diluted share, up from $0.60 a year earlier.Analysts polled by FactSet expected $0.60.Revenue for the three months ended June 30 was $535 million, up from $533.5 million a year earlier.Analysts surveyed by FactSet expected $527.5 million.The company expects Q3 adjusted diluted EPS of at least $0.62. Analysts project $0.64.Qiagen reaffirmed full-year adjusted EPS guidance of at least $2.43. Analysts project $2.41.The company's shares fell 2% in after-hours trading.

$QGEN
Research

Berenberg Downgrades QIAGEN to Hold From Buy, Cuts Price Target to $45.50 From $59

QIAGEN (QGEN) has an average rating of overweight and mean price target of $42.89, according to analysts polled by FactSet.

$QGEN
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) increased 0.3%.In corporate news, AstraZeneca (AZN) and its partner Ionis Pharmaceuticals (IONS) said Thursday that a phase 3 trial for eplontersen in people with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint. AstraZeneca shares fell 5%, and Ionis tumbled 23%.Qiagen (QGEN) is attracting early takeover interest from private equity firms, including EQT AB, Advent and KKR (KKR), with some potential bidders considering offers of at least $50 per share, Bloomberg reported. Qiagen shares jumped 10%.Fate Therapeutics (FATE) shares rose past 5% after the US Food and Drug Administration approved the company's investigational new drug application for FT839, a product candidate to treat autoimmune diseases.MetaVia (MTVA) shares climbed 11% after it said Thursday that all active patients in part 3 of its phase 1 trial for obesity drug candidate DA-1726 have completed dose titration and reached their highest planned doses of 48 mg and 64 mg.

$AZN$FATE$IONS$MTVA$QGEN
Sectors

Sector Update: Healthcare Stocks Decline in Afternoon Trading

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, AstraZeneca (AZN) and its partner Ionis Pharmaceuticals (IONS) said Thursday that a phase 3 trial for eplontersen in people with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint. AstraZeneca shares fell 5.4%, and Ionis tumbled 24%.Qiagen (QGEN) is attracting early takeover interest from private equity firms, including EQT AB, Advent and KKR (KKR), with some potential bidders considering offers of at least $50 per share, Bloomberg reported. Qiagen shares jumped past 10%.MetaVia (MTVA) shares rose 9% after it said Thursday that all active patients in part 3 of its phase 1 trial for obesity drug candidate DA-1726 have completed dose titration and reached their highest planned doses of 48 mg and 64 mg.

$AZN$IONS$MTVA$QGEN
Wire

Market Chatter: Qiagen Attracts Early Takeover Interest From EQT, Advent, KKR

Qiagen (QGEN) is attracting early takeover interest from private equity firms including EQT (EQT), Advent and KKR (KKR), with some potential bidders considering offers of at least $50 per share, Bloomberg reported Thursday, citing people familiar with the situation.Qiagen, which has been conducting a strategic review with advisers, could also draw interest from additional buyout firms and strategic acquirers. Deliberations are ongoing and there is no certainty they will result in a transaction, according to the report.Qiagen shares rose as much as 14% in US trading before trimming gains to trade up about 11%, valuing the company at roughly $8.7 billion, the report said.Qiagen, EQT, Advent and KKR did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $42.68, Change: $+4.68, Percent Change: +12.32%

$EQT$KKR$QGEN
Wire

Qiagen Attracts Early Takeover Interest From EQT, Advent, KKR, Bloomberg Reports

Qiagen Attracts Early Takeover Interest From EQT, Advent, KKR, Bloomberg Reports

$KKR$QGEN
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Qiagen

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target price of USD36, implying a 2026 P/E of 14.7x. This is at a discount to its historical average (20x-22x) to reflect the headwinds on its key growth contributor QuantiFERON, along with increased geopolitical and management uncertainties. This is partly cushioned by growth opportunities from other key products and improving shareholder returns. Qiagen published its full Q1 2026 results, which were in line with the preliminary results released in April. Q1 2026 net sales fell 1% CER dragged by QuantiFERON sales declining 5% CER due to reduced immigration testing demand in the U.S. and Middle East. In April, Qiagen downgraded 2026 guidance to 1%-2% CER sales growth from at least 5% and adjusted EPS to at least USD2.43 CER from USD2.50, and expect stronger trends in H2 supported by acquisition benefits and sequential QuantiFERON improvement. Our EPS estimates remained unchanged given the full Q1 results were in line with the preliminary figures.

$QGEN
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Qiagen

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to USD36 from USD54, and we trim our EPS estimates to USD2.45 from USD2.53 for 2026 and to USD2.64 from USD2.74 for 2027 in light of the guidance cut. The target price implies a 2026 P/E of 14.7x, below its historical average of 20x-22x to reflect headwinds on its key growth contributor QuantiFERON. Qiagen's preliminary Q1 2026 net sales fell 1% CER, missing the company's outlook for at least 1% growth, dragged by QuantiFERON (-5% CER) due to reduced immigration testing demand in the U.S. and Middle East. Given the slow start to the year, Qiagen downgraded 2026 guidance to 1%-2% CER sales growth from at least 5% and adjusted EPS to at least USD2.43 CER from USD2.50. We view the sales miss and lowered outlook as disappointing. We still see QuantiFERON as a main growth contributor over the long term, thus monitoring progress in other patient testing groups remains key. Full Q1 results are scheduled for May 6, 2026.

$QGEN
Research

Baird Upgrades QIAGEN to Outperform From Neutral, Cuts Price Target to $43 From $53

QIAGEN (QGEN) has an average rating of overweight and mean price target of $47.69, according to analysts polled by FactSet.

$QGEN
Research

Research Alert: Qiagen Cuts 2026 Outlook As Q1 Sales Miss On Weak Quantiferon Testing

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Qiagen's preliminary Q1 2026 net sales fell by 1% CER, missing the company's outlook for at least 1% growth, while reported sales grew 2% to USD492M, below consensus' USD501M. Preliminary adjusted EPS of USD0.54 was in line with the outlook, though overall results were dragged by QuantiFERON sales declining 5% CER due to reduced immigration testing demand in the U.S. and Middle East. The company downgraded 2026 guidance to 1%-2% CER sales growth (from at least 5% previously) and adjusted EPS to at least USD2.43 CER (from USD2.50 previously), expecting stronger trends in 2H, supported by acquisition benefits and sequential QuantiFERON improvement. We view the sales miss and lowered outlook as disappointing, but still see QuantiFERON as a main growth contributor, while the Parse acquisition should strengthen Qiagen's competitive position. That said, monitoring progress in other patient testing groups for QuantiFERON remains key. Full Q1 results are scheduled for May 6, 2026.

$QGEN
Research

Barclays Downgrades QIAGEN to Equalweight From Overweight, Adjusts Price Target to $44 From $48

QIAGEN (QGEN) has an average rating of overweight and mean price target of $54.01, according to analysts polled by FactSet.

$QGEN

Track with the FINWIRES app suite

FolioX
FolioX
Track QGEN in your portfolio
WheelAI
WheelAI
Analyze QGEN options with the wheel strategy
StockInsider
StockInsider
See market sentiment on QGEN